Compliance to treatment guidelines and survival in women undergoing interval debulking surgery for advanced epithelial ovarian cancer

被引:2
|
作者
Shylasree, Thumkur S. [1 ]
Kattepur, Abhay K. [1 ]
Gupta, Monisha [1 ]
Ghosh, Jaya [2 ]
Maheshwari, Amita [1 ]
Bajpai, Jyoti [2 ]
Hawaldar, Rohini [3 ]
Gulia, Seema [2 ]
Deodhar, Kedar [4 ]
Popat, Palak [5 ]
Gupta, Sudeep [2 ]
Kerkar, Rajendra A. [1 ]
机构
[1] Tata Mem Hosp, Dept Gynecol Oncol, Mumbai, Maharashtra, India
[2] Tata Mem Hosp, Dept Med Oncol, Mumbai, Maharashtra, India
[3] Tata Mem Hosp, Dept Clin Res Methodol & Biostat, Mumbai, Maharashtra, India
[4] Tata Mem Hosp, Dept Pathol, Mumbai, Maharashtra, India
[5] Tata Mem Hosp, Dept Radiodiag, Mumbai, Maharashtra, India
关键词
advanced epithelial ovarian cancer; compliance; deviation; interval debulking surgery; survival; NEOADJUVANT CHEMOTHERAPY; CLINICAL-OUTCOMES; ADHERENCE;
D O I
10.1002/cnr2.1217
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
BackgroundOne of the primary treatment strategies for advanced epithelial ovarian cancers includes neoadjuvant chemotherapy (NACT) followed by interval debulking surgery (IDS) and adjuvant chemotherapy. Compliance to treatment is important to possibly improve outcomes. AimTo audit treatment compliance and its effect on overall survival (OS) and disease free survival (DFS) in women undergoing IDS. Methods and ResultsWomen diagnosed with advanced epithelial ovarian cancer undergoing IDS were included. Details of compliance to chemotherapy and surgery as per standard guidelines were assessed, and correlation with survival was studied. Reasons for protocol deviation at various levels were documented and analysed. A total of 182 patients were included. The total number of deviations was 134 with deviation at any level being 89 (48.9%) and at all levels 5%. Both patient- and treatment-related factors contributed towards deviation. Deviation or noncompliance towards treatment resulted in a significantly reduced 5-year OS (34.4% vs 58.2%; P = .001) compared with compliant patients, which retained its significance on multivariate analysis (P = .024) as well. ConclusionDeviation from treatment guidelines resulted in a significantly lower 5-year OS compared with those who remained treatment compliant. Both patient- and treatment-related factors contributed towards noncompliance and hence towards lower survival.
引用
收藏
页数:9
相关论文
共 50 条
  • [41] The role of interval debulking surgery in ovarian cancer
    Maria E. L. van der Burg
    Ignace Vergote
    Current Oncology Reports, 2003, 5 (6) : 473 - 481
  • [42] Complete Pathologic Response at Interval Debulking Surgery Following Neoadjuvant Chemotherapy Predicts Improved Survival in Women with Advanced Epithelial Ovarian Cancer in a Multi-institutional Cohort
    Liang, M.
    Prendergast, E.
    Staples, J.
    Holschneider, C.
    Cass, I.
    GYNECOLOGIC ONCOLOGY, 2016, 143 (01) : 197 - 197
  • [43] Clinical significance of primary debulking surgery and neoadjuvant chemotherapy-interval debulking surgery in advanced ovarian cancer
    Nishio, Shin
    Ushijima, Kimio
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2020, 50 (04) : 379 - 386
  • [44] The Effect of the Interval from the Third Cycle of Neoadjuvant Chemotherapy to Interval Debulking Surgery on the Surgical Results in Advanced Epithelial Ovarian Cancer
    Mahmoud Hanafy Meleis
    Ahmed Mohammed Samy El-Agwany
    Indian Journal of Gynecologic Oncology, 2016, 14 (1)
  • [45] THE CLINICAL CHARACTERISTICS IN DETERMINING THE OPTIMUM TIMING OF INTERVAL DEBULKING SURGERY IN PATIENTS WITH ADVANCED EPITHELIAL OVARIAN CANCER.
    Morimoto, A.
    Nagao, S.
    Kogiku, A.
    Yamamoto, K.
    Miwa, M.
    Wakahashi, S.
    Ichida, K.
    Sudo, T.
    Yamaguchi, S.
    Fujiwara, K.
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2014, 24 (09) : 131 - 131
  • [46] The Effect of the Interval from the Third Cycle of Neoadjuvant Chemotherapy to Interval Debulking Surgery on the Surgical Results in Advanced Epithelial Ovarian Cancer
    Meleis, Mahmoud Hanafy
    El-Agwany, Ahmed Mohammed Samy
    INDIAN JOURNAL OF GYNECOLOGIC ONCOLOGY, 2016, 14 (01)
  • [47] Interval Debulking Surgery (IDS) after Induction Chemotherapy for Patients with Advanced Epithelial Ovarian Cancer: A Retrospective Analysis
    Mayer, C.
    Anastasiou, E.
    Bischofs, E.
    Bruckner, T.
    Fersis, N.
    Sohn, C.
    Eichbaum, M.
    GEBURTSHILFE UND FRAUENHEILKUNDE, 2011, 71 (05) : 405 - 411
  • [48] Impact of the Time Interval Between Primary Debulking Surgery and Start of Adjuvant Chemotherapy in Advanced Epithelial Ovarian Cancer
    Lin, Hao
    Chen, Wen-Hsin
    Wu, Chen-Hsuan
    Ou, Yu-Che
    Chen, Yu-Jen
    Chen, Ying-Yi
    Lin, Yu-Han
    Fu, Hung-Chun
    CANCER MANAGEMENT AND RESEARCH, 2021, 13 : 5413 - 5422
  • [49] Robotic interval debulking surgery for advanced epithelial ovarian cancer: current challenge or future direction? A systematic review
    Victoria Psomiadou
    Anastasia Prodromidou
    Alexandros Fotiou
    Sofia Lekka
    Christos Iavazzo
    Journal of Robotic Surgery, 2021, 15 : 155 - 163
  • [50] Non-invasive predictive factors of complete cytoreduction at interval debulking surgery in advanced epithelial ovarian cancer
    Candotti, Giorgio
    Pavone, Giacomo
    Bocciolone, Luca
    Vasta, Francesca
    Galli, Federica
    Di Filippo, Marianna
    Rabaiotti, Emanuela
    Bergamini, Alice
    Shai, Daniel
    De Marzi, Patrizia
    Pella, Francesca
    Taccagni, Gianluca
    Sant'Angelo, Miriam
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2024, 34 (SUPPL_1) : A350 - A350